COMPANY / Overview


Biosolution Co., Ltd.: A Leader in Cell-Based Biotechnology

About Us

The company has obtained sale authorization of KeraHeal as a cell-based therapy product in 2006 and was registered as part of the industrial insurance benefits in 2009. In October 2015, we obtained sale authorization and industrial insurance benefit registration for Keraheal-Allo which is a thermosensitive hydrogel-type allogeneic keratinocyte therapy product. in 2019, CartiLife was granted sale authorization as an autologous chondrocyte derived cartilaginous cell therapy for structural restoration of cartilage defect and symptom alleviation.

Our tissue model has been registered as an international standard model in the OECD guidelines in 2019. Our human tissue models are sold for the purpose of assessing the toxicity and effectiveness of chemicals, cosmetics, household goods and medicines on the human body, and also used to provide research service by the company.

Human stem cell growth media StemSoo (스템수) and the peptide component BSP-11 are sold as cosmetic ingredients which are capable of improving wrinkles, skin whitening and elasticity restoration.

Business Plans and Strategy

As our live expectancy has grown and medical welfare benefits have increased, ‘Tissue Engineering and Regenerative Medicine’ hats appeared as a new area in medicine in the 21st century known to possibly replace defective body parts due to degenerative or genetic disorders, disabilities, accidents and diseases. As cell therapeutics cure diseases at the fundamental level by improving the level of decay in cell and tissue functions, demand in new medications using cell therapeutics have taken its course on a rising slope. With high expectations in the vast market potential and effective value on cell therapeutics, Biosolution Co., Ltd. is concentrating on the R&D and commercialization of these cell therapeutics.

Biosolution Co., Ltd. has developed many products engrafted by the next-gen cell based applied technology using diverse cell sources. By applying this cell based technology on different types of cells, we continuously perform research on next-gen products utilizing reinforced technology to improve on existing products, and technology to develop products ased on different indications; this keeps Biosolution Co., Ltd. in the lead for marketability and technological competitiveness in a rapidly changing market.

In preparation for the future, we are currently pursuing the implementation of cell manipulation technologies derived from our skin therapy products into the development of human tissue models, and are committed to stepping up as the standard in human tissue models through steps such as OECD International Test Standard registration and expansion of business in and out of South Korea. As a worldwide leader in the biological industry, Biosolution Co., Ltd. is willing to contribute to the health and wellbeing of mankind with our cell based application technologies.

Core R&D Technology
  • Cell Based Application Technology
Areas of Business
  • Cell-based therapeutics
  • Peptide-based medical products/devices
  • Human tissue models
  • Stem cell / peptide based cosmeceutics
  • Contracted Research Services
Company Biosolution Co., Ltd.
Date Established January 14th, 2000
Capital 3 Billion KRW
Headquarters & Research Lab 5F, Seoul Technopark, Gongneung-Ro 232, Nowon-gu, Seoul
Manufacturing Dept B1 & 1F & 5F, Seoul Technopark, Gongneung-dong, Nowon-gu, Seoul
Business Development, Manufacturing, Sales of Cell Therapeutics
Products Cell Therapeutics, Human Tissue Models, Wound Therapeutics, Stem Cell Media Extract Cosmeceutics
Website www.biosolutions.co.kr